Kelly Corbitt

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Neuropathic Pain

Systemic Lupus Erythematosus

Top Venues

ACR open rheumatology

The Journal of rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Kelly Corbitt, Philip M Carlucci, Brooke Cohen, Mala Masson, Amit Saxena, H Michael Belmont, Chung-E Tseng, Kamil E Barbour, Heather Gold, Jill P Buyon, Peter M Izmirly
Clinical and Serologic Phenotyping and Damage Indices in Patients With Systemic Lupus Erythematosus With and Without Fibromyalgia. ACR open rheumatology 6 (4) (2024)
Kelly Corbitt, Philip M Carlucci, Brooke Cohen, Mala Masson, Amit Saxena, H Michael Belmont, Chung-E Tseng, Kamil E Barbour, Heather Gold, Jill P Buyon, Peter M Izmirly
Clinical and Serologic Phenotyping and Damage Indices in Patients With Systemic Lupus Erythematosus With and Without Fibromyalgia. ACR open rheumatology 6 (4) (2024)
Kelly Corbitt, Philip M Carlucci, Brooke Cohen, Mala Masson, Amit Saxena, H Michael Belmont, Chung-E Tseng, Kamil E Barbour, Heather Gold, Jill P Buyon, Peter M Izmirly
Clinical and Serologic Phenotyping and Damage Indices in Patients With Systemic Lupus Erythematosus With and Without Fibromyalgia. ACR open rheumatology 6 (4) (2024)
Kelly Corbitt, Philip M Carlucci, Brooke Cohen, Mala Masson, Amit Saxena, H Michael Belmont, Chung-E Tseng, Kamil E Barbour, Heather Gold, Jill P Buyon, Peter M Izmirly
Clinical and Serologic Phenotyping and Damage Indices in Patients With Systemic Lupus Erythematosus With and Without Fibromyalgia. ACR open rheumatology 6 (4) (2024)
Kelly Corbitt, Philip M Carlucci, Brooke Cohen, Mala Masson, Amit Saxena, H Michael Belmont, Chung-E Tseng, Kamil E Barbour, Heather Gold, Jill P Buyon, Peter M Izmirly
Clinical and Serologic Phenotyping and Damage Indices in Patients With Systemic Lupus Erythematosus With and Without Fibromyalgia. ACR open rheumatology (2024)
Kelly Corbitt, Peter M Izmirly, Amit Saxena
Molnupiravir and Nirmatelvir/Ritonavir in the Treatment of Patients With Systemic Autoimmune Rheumatic Disease With SARS-CoV-2. The Journal of rheumatology (2023)